(TSVT) 2Seventy Bio - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9013841070
TSVT: Cancer, Gene, Therapy, Cell, Treatment, Products
2Seventy Bio, Inc. (NASDAQ: TSVT) is a clinical-stage cell and gene therapy company dedicated to pioneering transformative treatments for cancer. The companys lead product, Abecma, is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, currently under investigation for the treatment of relapsed or refractory multiple myeloma. This innovative approach harnesses the bodys immune system to target cancer cells, distinguishing it in the CAR-T landscape. 2Seventy Bios strategic collaboration with Bristol Myers Squibb underscores its commitment to advancing cancer treatments, leveraging shared expertise to enhance therapeutic outcomes.
Beyond Abecma, 2Seventy Bio is actively exploring its application in other hematologic malignancies, showcasing a robust pipeline aimed at addressing unmet medical needs. The companys focus extends to developing next-generation CAR-T therapies, emphasizing improved efficacy and reduced side effects. With a strong emphasis on research and development, 2Seventy Bio is navigating the competitive CAR-T landscape, differentiating itself through innovative manufacturing and strategic partnerships.
3-Month Forecast: Based on technical indicators, TSVTs stock is in a downtrend, trading below its 200-day SMA. The convergence of 20-day and 50-day SMAs suggests potential stabilization or a break-out point. Low ATR indicates reduced volatility. Fundamentally, despite a high P/S ratio and negative RoE, the market cap reflects speculative interest. The stock may face resistance near $3.00, with support around $2.30. Positive clinical data could drive upside, while negative results may lead to further decline.
Additional Sources for TSVT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TSVT Stock Overview
| Market Cap in USD | 137m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2021-11-03 |
TSVT Stock Ratings
| Growth 5y | -63.4% |
| Fundamental | -43.0% |
| Dividend | 0.0% |
| Rel. Strength Industry | 35.3 |
| Analysts | 3.6/5 |
| Fair Price Momentum | 3.88 USD |
| Fair Price DCF | - |
TSVT Dividends
No Dividends PaidTSVT Growth Ratios
| Growth Correlation 3m | -23.9% |
| Growth Correlation 12m | -57.2% |
| Growth Correlation 5y | -87.8% |
| CAGR 5y | -26.26% |
| CAGR/Max DD 5y | -0.27 |
| Sharpe Ratio 12m | -0.52 |
| Alpha | 12.89 |
| Beta | 1.22 |
| Volatility | 255.08% |
| Current Volume | 2037.3k |
| Average Volume 20d | 308.3k |
As of March 15, 2025, the stock is trading at USD 4.95 with a total of 2,037,344 shares traded.
Over the past week, the price has changed by +86.09%, over one month by +94.88%, over three months by +51.84% and over the past year by +25.00%.
Probably not. Based on ValueRay Fundamental Analyses, 2Seventy Bio (NASDAQ:TSVT) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -43.00 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TSVT as of March 2025 is 3.88. This means that TSVT is currently overvalued and has a potential downside of -21.62%.
2Seventy Bio has received a consensus analysts rating of 3.60. Therefor, it is recommend to hold TSVT.
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, TSVT 2Seventy Bio will be worth about 4.2 in March 2026. The stock is currently trading at 4.95. This means that the stock has a potential downside of -14.95%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 7.5 | 51.5% |
| Analysts Target Price | 6.8 | 36.4% |
| ValueRay Target Price | 4.2 | -14.9% |